# Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

> **NCT00335738** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 331 (actual)

## Conditions studied

- Intraocular Retinoblastoma

## Interventions

- **DRUG:** liposomal vincristine sulfate
- **DRUG:** carboplatin
- **DRUG:** etoposide

## Key facts

- **NCT ID:** NCT00335738
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2011-09
- **Final completion:** 2020-09-30
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2021-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00335738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00335738, "Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00335738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*